Immuno-oncology
Commentary
Change in end-of-life cancer care imperative
With the passage of the Medicare Access and CHIP Reauthorization Act, changes to how cancer care is delivered are fast approaching. This...
Conference Coverage
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
COPENHAGEN – Adding the PD-1 checkpoint inhibitor pembrolizumab (Keytruda) to a standard platinum-doublet chemotherapy regimen nearly doubled...
Conference Coverage
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
COPENHAGEN – Checkpoint inhibitors have shown good efficacy for treatment of advanced NSCLC, but use in the neoadjuvant setting is still...
News
10 recommendations for the Cancer Moonshot
Responding to the Cancer Moonshot initiative, a panel of scientists, clinicians, patient advocates, and industry representatives has issued 10...
News
Gene profile predicts RCC response to nivolumab
Many patients with advanced RCC have tumors that do not respond to immune checkpoint inhibitors targeted against the programmed death-1 (PD-1)...
News
SU2C announces researcher-industry collaboration on immunotherapy
News
Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
Among patients with immune-mediated diseases and a history of malignancy, cancer recurrence rates were similar regardless of whether they received...
News
Pembrolizumab paired with immunostimulator is safe and tolerable
Combining an immunostimulator with pembrolizumab had good tolerability and safety, in a small phase Ib study.
Conference Coverage
Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapies
Key clinical point: Neoadjuvant chemotherapy alters the immune microenvironment in patients with advanced ovarian cancer. Major finding:...
News
NRAS mutations predict immunotherapy outcomes in melanoma patients
Key clinical point: Patients with advanced melanoma and mutations in the NRAS gene had better responses to immunotherapy than did those without...